Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03023319 · ClinicalTrials.gov registry record · Phase 1
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
A Phase 1 study of Ovarian Cancer and Bladder Cancer, sponsored by Nagla Abdel Karim.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03023319 is a Phase 1 study of Ovarian Cancer and Bladder Cancer that has completed, run by Nagla Abdel Karim. The registered enrollment target is 6 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03023319, a Phase 1 study of Ovarian Cancer and Bladder Cancer, has completed, sponsored by Nagla Abdel Karim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Conditions Studied
Interventions
- DRUG Pemetrexed
- DRUG Bosutinib
Study Locations (1)
Georgia
- Augusta University Georgia Cancer Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2022-05-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03023319
The ClinicalTrials.gov registry entry for NCT03023319 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Nagla Abdel Karim, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pemetrexed is the first listed.
NCT03023319 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03023319 about?
NCT03023319 is a clinical study titled "Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors". This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see wha...
What is the current status of trial NCT03023319?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-12-10. Estimated completion is 2022-05-10.
What conditions does trial NCT03023319 study?
This clinical trial studies the following conditions: Ovarian Cancer, Bladder Cancer, Carcinoma, Non-Small Cell Lung, Mesothelioma, Peritoneal Cancer.
What interventions are being tested in trial NCT03023319?
The interventions under investigation include: Pemetrexed (DRUG), Bosutinib (DRUG).
Who is sponsoring clinical trial NCT03023319?
This trial is sponsored by Nagla Abdel Karim, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03023319 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.